The COVID-19 pandemic led to a unforeseen advancement in medical product technology with the emergency use authorization of the first-ever mRNA gene technology ("COVID vaccines")—BNT162b2 (Pfizer-BioNTech) and mRNA-1273 (Moderna). These "vaccines" utilized synthetic mRNA molecules that encode the SARS-CoV-2 Spike protein, encapsulated in synthetic lipid nanoparticles (LNPs), allowing for the widespread delivery of mRNA into virtually all human cells. This technology is intended to mimic a natural infection, enabling the host cells to produce the viral spike protein (which happens to induce the well-known cytokine storm, and lasts for months), which then triggers a hyperactive immune response that can lead to severe inflammation and damage to tissues. One of the more concerning observations is that mRNA vaccines may stimulate the production of IgG4 antibodies, otherwise known as immunoglobulin G, subtype 4. More specifically, IgG4 antibodies induced by repeated vaccination appear to generate immune tolerance to the SARS-CoV-2 spike protein. Immune tolerance means the immune system is less likely to mount a strong inflammatory response to the antigen (in this case, the Spike protein of SARS-CoV-2), which can lead to a host of various immune problems, including but not limited to cancer. "Emerging evidence suggests that the reported increase in IgG4 levels detected after repeated vaccination with the mRNA vaccines may not be a protective mechanism; rather, it constitutes an immune tolerance mechanism to the spike protein that could promote unopposed SARS-CoV2 infection and replication by suppressing natural antiviral responses." What are immunoglobulins?Immunoglobulins (antibodies) play a vital role in the human immune system, acting as the primary defense against infections and foreign substances. Among the various immunoglobulin classes (IgA, IgE, IgM, and IgG), IgG is the most abundant and is subdivided into four subclasses: IgG1, IgG2, IgG3, and IgG4. These subclasses differ in their structure, physiological roles, and interaction with immune cells. While IgG1 is the most common, accounting for the majority of serum immunoglobulins (66%), IgG4 represents a smaller fraction (4%) but has gained significant interest due to its unique properties and effects on the immune system. Structure and Unusual Behavior of IgG4IgG4 differs from other subclasses due to its limited ability to activate the complement system, a key immune mechanism responsible for destroying infected cells. This characteristic has led to IgG4 being classified as an unusual antibody. One of its most intriguing features is Fab arm exchange, a process in which the two halves of an IgG4 antibody can dissociate and recombine with halves from other IgG4 antibodies. This creates bi-specific antibodies with two distinct Fab arms, reducing their ability to form immune complexes and stimulate immune responses. IgG4 antibodies have low affinity for C1q and Fc receptors, which limits their capacity to initiate effector responses. However, this bi-specific structure enables IgG4 to potentially block the inflammatory effects of other antibody classes, such as IgG1 or IgE, by displacing their antigen-binding capabilities. This property contributes to IgG4's role as a "blocking antibody", known for its anti-inflammatory effects. Think of C1q as a "signal booster" in the immune system. When an antibody (like other IgGs) sticks to a virus or bacteria, C1q can attach to the antibody and kickstart a bigger immune response. This response helps destroy the invader by activating a defense system called the complement system, which can puncture the bad cell or attract more immune cells to the area to help fight. However, IgG4 doesn’t do this as effectively as other types of IgG antibodies. It has a much weaker ability to call on C1q, meaning it doesn't start this complement attack as strongly. This makes IgG4 more of a "quiet observer" in some situations, which can be helpful in avoiding too much inflammation. Fc receptors are like "docking stations" found on the surface of immune cells. These docking stations grab onto the "tail" end of antibodies (this part of the antibody is called the Fc region) and help immune cells, like phagocytes (cells that eat invaders), detect and destroy harmful germs or infected cells. IgG4 doesn’t bind well to these Fc receptors, so it doesn’t trigger a strong immune attack like other antibodies (such as IgG1). In Other Words:
IgG4-Related Systemic DiseaseIgG4 is linked to a broad range of clinical conditions, collectively referred to as IgG4-related systemic disease. This condition involves multiple organs, characterized by significant fibrosis, infiltration of IgG4-positive plasma cells, and dispersed immune cell infiltrates. Although the disease can affect different organs, common histological (anatomical tissue) features are observed, such as tissue fibrosis and immune cell infiltration. IgG4: Friend or Foe?The role of IgG4 in human health is complex, with evidence pointing to both protective and pathogenic effects. In allergy immunotherapy, for example, IgG4 is often viewed as a protective antibody due to its ability to reduce inflammation and prevent IgE-mediated allergic reactions. Elevated levels of antigen-specific IgG4 are associated with successful desensitization to allergens, allowing for the development of immune tolerance. During prolonged exposure to allergens, IgG4 competes with IgE for antigen binding, effectively neutralizing allergic responses without activating immune effector cells. However, IgG4 can also be involved in pathogenic processes. In some autoimmune diseases, such as pemphigus vulgaris (autoimmune disease that causes blistering of the skin and mucous membranes, such as the mouth, throat, and genitals), IgG4 plays a role in the disease’s progression by contributing to tissue damage. Additionally, IgG4 has been linked to the suppression of immune responses in certain types of cancer, where its blocking ability may inhibit the immune system's capacity to fight tumor cells. Protective Role in Allergy ImmunotherapyIn the context of allergy immunotherapy, IgG4’s lack of effector function and its capacity for half-antibody exchange raise questions about its role in modulating immune responses. Several studies have demonstrated that high levels of antigen-specific IgG4 are associated with successful outcomes in allergen-specific immunotherapy. This is because IgG4 can inhibit the effects of IgE, the antibody responsible for allergic reactions. Through allergen-specific memory T- and B-cell responses, the immune system adapts to tolerate allergens, reducing chronic inflammation and allergic responses. This process is crucial for building a more robust and balanced immune system. IgG4-Related Disease and Its PathogenesisIgG4-related disease (IgG4-RD) is a condition that causes inflammation and tissue damage in various parts of the body. It is marked by high levels of a specific type of immune cell called IgG4 plasma cells, which are found in the affected tissues, and higher-than-normal levels of IgG4 antibodies in the blood. IgG4-RD includes a wide variety of diseases:
It also plays a significant role in the pathogenesis of at least 13 autoimmune disorders, including rheumatoid arthritis, and myasthenia gravis. The clinical manifestations of IgG4-RD are usually tumor-like masses or organ enlargement, which result from dense tissue infiltration by immune cells and expansion of the extra-cellular matrix. One or more organs are affected; the 11 organs considered typical of IgG4-RD including the:
In certain autoimmune diseases, IgG4 levels correlate with disease severity, and in experimental models, IgG4 has been shown to cause disease manifestations when injected into animals. This indicates the pathogenic role of IgG4 in these disorders. IgG4’s Role in CancerRecent studies suggest that IgG4 antibodies may play a role in immune evasion by cancer cells, contributing to cancer progression. Immune checkpoint inhibitors (ICBs) are commonly used in cancer immunotherapy to block proteins like PD-1 (programmed cell death protein 1) and allow the immune system to attack cancer cells. However, IgG4 antibodies, including PD-1 antibodies, have been linked to cases of rapid disease progression, known as hyper-progressive disease (HPD). IgG4 antibodies were found to interfere with anti-tumor immune responses, blocking the ability of other antibodies (such as IgG1) to target and destroy cancer cells. This was demonstrated in studies of cancers like malignant melanoma, where locally produced IgG4 antibodies hindered the immune system's response, allowing tumors to grow unchecked. Studies using animal models confirmed that IgG4 promotes tumor growth by blocking local immune responses. For example, in a breast cancer model, the local administration of IgG4 significantly accelerated tumor growth compared to controls. These findings suggest that IgG4 antibodies assist cancer cells in escaping immune detection, facilitating tumor progression. Although immune checkpoint inhibitors targeting PD-1 are effective in some cancers, their IgG4 subclass raises concerns about potential side effects, including autoimmune reactions and rapid tumor progression. IgG4's role in blocking immune responses may explain the occurrence of hyper-progressive disease in some patients undergoing cancer immunotherapy. Studies have shown that certain cancers, including malignant melanoma, extrahepatic cholangiocarcinoma, and pancreatic cancer, often have an abundance of IgG4-positive plasma cells in and around the tumor. A groundbreaking study by Karagiannis et al. revealed that cancer-specific IgG4 antibodies, unlike their IgG1 counterparts, do not activate the immune processes required to destroy cancer cells. Instead, IgG4 appears to interfere with IgG1's ability to promote tumor cell death, allowing the cancer to evade immune attack. This mechanism of immune escape enables the tumor to grow unchecked, making IgG4 a key player in cancer progression. IgG4's Impact on Tumor Immune Evasion Karagiannis and colleagues demonstrated that tumors producing IgG4 can actively inhibit the immune system’s ability to kill cancer cells. In their study, they found that IL-4 and IL-10, cytokines associated with immune regulation, were elevated in cancerous tissues, leading to increased IgG4 production. The research showed that IgG4 not only failed to fight tumors but also blocked other immune antibodies, like IgG1, from effectively doing so. This was further supported by experiments using immunocompetent mice models, where the introduction of IgG4 antibodies sped up tumor growth. These findings suggest that IgG4 plays a direct role in helping cancers evade the immune system. IgG4 and Cancer Immunotherapy IgG4’s interference with the immune system extends to cancer immunotherapy. Specifically, nivolumab, a PD-1 blocking antibody used in cancer treatment, belongs to the IgG4 class. While effective in some cases, its IgG4 nature may also contribute to the rapid progression of cancer in others. In mouse studies, treatment with nivolumab led to faster tumor growth when compared to controls, suggesting that IgG4’s role in cancer therapy may have unintended negative effects. The connection between IgG4 and cancer highlights the challenges of using ICIs. On the one hand, PD-1 inhibitors can stimulate the immune system to fight cancer, but on the other hand, they may inadvertently promote immune evasion and tumor growth when IgG4 is involved. Cancers Appearing in Ways Never Before Seen After COVID Vaccinations: Dr. Harvey RischDr. Harvey Risch, professor emeritus of epidemiology at the Yale School of Public Health and Yale School of Medicine, has voiced concerns about a potential rise in cancer cases following COVID-19 vaccinations. Dr. Risch, whose research focuses on cancer causes and prevention, recently shared his observations in an interview with EpochTV’s American Thought Leaders. According to him, oncology clinics are facing significant delays in appointment availability, especially in New York, where patients are now waiting months instead of weeks for cancer-related consultations. One of the key points Dr. Risch highlights is the appearance of unusual cancer cases, particularly in younger individuals. For instance, he cites cases of 25-year-olds developing colon cancer despite having no family history, a rare occurrence under normal circumstances. He believes that something must be triggering these early-onset cancers, which don't align with traditional understandings of cancer development, which can take years or even decades to manifest. Dr. Risch explained that a healthy immune system plays a crucial role in detecting and neutralizing cancerous cells before they can multiply. However, if the immune system is weakened or compromised, it may fail to perform this function effectively, allowing cancerous cells to grow unchecked. He believes that in some people, the COVID-19 vaccines have impaired their immune systems to varying degrees, potentially leading to an increased risk of developing cancer, recurring infections, or other serious health conditions. Dr. Risch used the term “turbo cancers” to describe aggressive forms of cancer that seem to develop and progress at an unusually fast rate. He mentioned cases where cancers, such as breast cancer, are reappearing in vaccinated women much sooner than expected. Typically, breast cancer that returns after surgery takes around two decades to reappear, but in some of these cases, it has resurfaced in much shorter timeframes. He also reported instances where tumors grew dramatically in the short period between initial diagnosis and follow-up appointments, surprising oncologists who are accustomed to slower cancer progression. In light of these findings, Dr. Risch encourages individuals to be particularly attentive to any new or unusual symptoms in their bodies. Being proactive and aware of potential warning signs could help detect issues earlier. Dr. Risch also discussed the way medical agencies track adverse events following vaccination. Officially, a person is not considered "vaccinated" until two weeks after their shot, meaning any negative reactions occurring before then are often counted as happening to unvaccinated individuals. However, Dr. Risch emphasized that a significant portion of adverse reactions, including serious health issues, can occur within the first few days of vaccination, yet they are being incorrectly attributed. Dr. Risch criticized how public health policies were handled during the pandemic, saying key principles of public health were abandoned early on. He cited the denial of early treatments for COVID-19 and what he believes were unnecessary vaccinations, calling the approach a “colossal failure.” In his view, a lot of the current fear surrounding new COVID variants is being fueled by propaganda designed to promote more vaccinations, rather than genuine concern for public health. While Dr. Risch acknowledges that the individual risk of a severe adverse reaction to the vaccine is relatively low, when millions of people are vaccinated, even small risks can translate to large numbers of individuals experiencing serious health consequences. According to him, these reactions can sometimes be worse than the virus itself, leaving hundreds of thousands of people with injuries or long-term health problems. Given the mild nature of current COVID-19 variants, Dr. Risch strongly advises against receiving more mRNA vaccines. He believes that most people already have some immunity from previous infections and that the new variants are not life-threatening. For Dr. Risch, the focus should be on managing these illnesses as we do with other common infections, like the flu, without resorting to unnecessary vaccinations. In summary, Dr. Risch’s concerns reflect growing skepticism over the long-term effects of COVID-19 vaccines, particularly their potential link to an increase in cancer cases. His call for awareness, both from individuals and the medical community, underscores the need for further research into the vaccines’ impact on the immune system and overall health. Hyper-Progressive Disease and Immune EscapeThe phenomenon of HPD—where patients experience accelerated cancer progression during treatment—may be partly explained by IgG4’s involvement. As tumors produce more IgG4 antibodies, they hinder immune responses and facilitate tumor survival and growth. This could explain why a subset of patients receiving PD-1 inhibitors experience HPD rather than remission. IgG4 and AutoimmunityInterestingly, while IgG4 can contribute to immune suppression in cancer, it may also lead to autoimmune reactions. In some cases, the use of PD-1 inhibitors has been associated with the development of acute myocarditis, a severe inflammation of the heart muscle. This potentially life-threatening condition highlights the delicate balance ICIs strike between immune stimulation and suppression. antibody class switchingAntibody class switching is like your immune system changing the type of weapon it uses to fight an infection. When you get vaccinated, your immune system makes antibodies—proteins that help protect you by recognizing and neutralizing harmful invaders like viruses. At first, your body might make certain types of antibodies, like IgG1 and IgG3, which are really good at attacking and destroying a virus. But after repeated exposure to the same vaccine or virus (like with the repeated doses of the COVID-19 mRNA vaccines), your body may shift gears and start producing a different type of antibody, called IgG4. IgG4 antibodies act more like peacekeepers than attackers. Instead of creating a strong inflammatory response to destroy invaders, IgG4 helps calm the immune system down. This happens after the immune system has been repeatedly exposed to the same thing over time, which is why it can occur after multiple mRNA vaccine doses. While this shift to IgG4 antibodies can help prevent excessive inflammation, it also means the immune response might be less aggressive, particularly in detecting and neutralizing immune threats. In the case of the COVID-19 mRNA vaccines, scientists have noticed that repeated doses can lead to higher levels of IgG4, and it appears to leading to higher rates of cancer and other IgG4-related diseases. The body might be learning to tolerate the spike protein (the part of the virus the vaccine targets), but the effects of this shift on long-term immunity are arguably worse than the disease itself. The Impact of Antigen Dose and Repeated Vaccination on IgG4 Antibody ProductionVaccines have long been claimed to be a cornerstone in disease prevention, but recent research has shown that certain vaccines can induce the production of IgG4 antibodies. While the mRNA COVID-19 "vaccines" have brought this response into focus, it's not unique to them—vaccines for diseases like HIV, malaria, pertussis, tetanus toxoid (TT) vaccine and the respiratory syncytial virus (RSV) have also been associated with IgG4 production. This antibody class switch is influenced by three key factors: antigen concentration, repeated vaccination, and the type of vaccine used.
In contrast, adenovirus-based vaccines like AstraZeneca's did not elicit such a long-lasting IgG4 response (despite them being suspended in 18 countries for adverse events). The link between higher antigen doses and immune tolerance is well-documented: too much antigen can lead to T-cell exhaustion and immune tolerance, weakening the immune system’s ability to fight infections. While the traditional view has supported the idea that “more is better” when it comes to antigen doses for vaccines, especially in cases like HIV or tuberculosis where there are no clear immune predictors of protection, this approach is not without drawbacks. The following key concerns arise from excessive antigen dosing:
Studies have also shown that in some cases, lower vaccine doses can result in better T-cell responses. This has led experts to reconsider vaccine dosing strategies, suggesting that smaller doses may sometimes be more effective, especially in boosting immunity. 2. Repeated Vaccination Repeated exposure to vaccines, especially mRNA-based vaccines, can significantly influence the type of antibodies produced. After the initial two doses of COVID-19 mRNA vaccines, most individuals develop IgG1 and IgG3 antibodies, which are typically pro-inflammatory and play a key role in fighting infections. However, as more doses are administered, a shift occurs, with IgG4 levels increasing significantly, particularly after a third dose or subsequent infection with a SARS-CoV-2 variant. A group of 29 people got three doses of the Pfizer mRNA vaccine, Comirnaty. Blood samples were taken from them at different points: after each dose, and later during two follow-up visits, one about 7 months after the second shot and the other about 6 months after the third. During this time, 10 people got infected despite being vaccinated. Researchers measured specific immune responses (different types of antibodies) in their blood using special tests. Results below a certain threshold were marked as very low. The graphs show individual results and averages for the group. Only certain comparisons between the time points are shown in the data. This IgG4 response was not observed in those who received adenovirus-based vaccines. In one study, only recipients of the Pfizer mRNA vaccine exhibited this significant increase in IgG4 levels, particularly 5–6 months after the second vaccination. In contrast, other vaccine schedules, such as mixing Pfizer with AstraZeneca, did not show a similar IgG4 rise, emphasizing the unique nature of the mRNA vaccines in inducing this response. 3. The Consequences of Over-Vaccination Recent studies have raised concerns about the potential negative effects of over-vaccination with mRNA boosters (as of September 2024, the CDC has recommended the American public to administer nine doses of COVID "vaccines" since the onset of the pandemic). In mouse models, extended booster vaccination schedules diminished the effectiveness of the immune system against new infections, particularly for Delta and Omicron variants. The findings showed that excessive boosting resulted in:
This suggests that repeated vaccination may diminish the immune system's ability to respond to new infections or reinfections, potentially leading to more severe disease outcomes for those who become infected again after multiple booster doses. Interestingly, the increase in IgG4 antibodies after mRNA COVID-19 vaccinations does not appear to be caused by genetic predisposition. Around 50% of individuals showed a significant increase in IgG4 after their second mRNA vaccination, and this was consistent across different populations, indicating that repeated exposure to the antigen was the primary cause. This finding contradicts the traditional paradigm of vaccinology, where low antigen doses are generally recommended for booster shots. Both Pfizer and Moderna vaccines used the same antigen doses for primary and booster shots, leading to elevated IgG4 levels. The production of IgG4 antibodies following vaccination is influenced by several factors, including antigen dose, repeated exposure, and the type of vaccine. The unique ability of the mRNA vaccines to induce IgG4 antibody production—especially after multiple doses—raises important questions about long-term immunity and potential immune tolerance. As research continues, striking a balance between sufficient immune response and avoiding immune exhaustion will be crucial in optimizing vaccination strategies for future diseases. REferencesUversky, Vladimir N, et al. “IgG4 Antibodies Induced by Repeated Vaccination May Generate Immune Tolerance to the SARS-CoV-2 Spike Protein.” Vaccines, vol. 11, no. 5, 17 May 2023, pp. 991–991, www.ncbi.nlm.nih.gov/pmc/articles/PMC10222767/, https://doi.org/10.3390/vaccines11050991.
Koneczny, Inga. “Update on IgG4-Mediated Autoimmune Diseases: New Insights and New Family Members.” Autoimmunity Reviews, vol. 19, no. 10, Oct. 2020, p. 102646, https://doi.org/10.1016/j.autrev.2020.102646. Boretti, Alberto. “MRNA Vaccine Boosters and Impaired Immune System Response in Immune Compromised Individuals: A Narrative Review.” Clinical and Experimental Medicine, vol. 24, no. 1, 27 Jan. 2024, www.ncbi.nlm.nih.gov/pmc/articles/PMC10821957/#:~:text=Immunocompromised%20individuals%20may%20not%20mount, https://doi.org/10.1007/s10238-023-01264-1. Perugino, Cory. “IgG4-Related Disease - Musculoskeletal and Connective Tissue Disorders.” Merck Manuals Professional Edition, Aug. 2023, www.merckmanuals.com/professional/musculoskeletal-and-connective-tissue-disorders/igg4-related-disease/igg4-related-disease. Rispens, Theo, and Maartje G Huijbers. “The Unique Properties of IgG4 and Its Roles in Health and Disease.” Nature Reviews Immunology, 24 Apr. 2023, https://doi.org/10.1038/s41577-023-00871-z. Brogna, Carlo, et al. “Detection of Recombinant Spike Protein in the Blood of Individuals Vaccinated against SARS‐CoV‐2: Possible Molecular Mechanisms.” PROTEOMICS - Clinical Applications, 31 Aug. 2023, https://doi.org/10.1002/prca.202300048. Irrgang, Pascal, et al. “Class Switch toward Noninflammatory, Spike-Specific IgG4 Antibodies after Repeated SARS-CoV-2 MRNA Vaccination.” Science Immunology, vol. 8, no. 79, 27 Jan. 2023, https://doi.org/10.1126/sciimmunol.ade2798. Efthymis Oraiopoulos, and Jan Jekielek. “Cancers Appearing in Ways Never before Seen after COVID Vaccinations: Dr. Harvey Risch.” The Epoch Times, 20 Sept. 2023, web.archive.org/web/20230923113807/www.theepochtimes.com/health/cancers-appearing-in-ways-never-before-seen-after-covid-vaccinations-dr-harvey-risch-5495364. Accessed 4 Oct. 2024. Goldman, Serge, et al. “Rapid Progression of Angioimmunoblastic T Cell Lymphoma Following BNT162b2 MRNA Vaccine Booster Shot: A Case Report.” Frontiers in Medicine, vol. 8, 25 Nov. 2021, www.ncbi.nlm.nih.gov/pmc/articles/PMC8656165/, https://doi.org/10.3389/fmed.2021.798095. Accessed 15 May 2024.
0 Comments
Investigating the Potential Link Between COVID-19 Vaccination and Neurodegenerative Diseases7/28/2024 The COVID-19 pandemic has introduced numerous challenges, including concerns about the potential side effects of vaccines. Recently, there has been increasing interest in understanding whether COVID-19 vaccination might be associated with neurodegenerative diseases, particularly Alzheimer’s disease (AD) and its prodromal state, mild cognitive impairment (MCI). A recent groundbreaking study published by Oxford University Press on behalf of the Association of Physicians has investigated the potential association between COVID-19 vaccination and the onset of Alzheimer’s disease and mild cognitive impairment. A nationwide, retrospective cohort design was utilized, leveraging data from the Korean National Health Insurance Service. The study focused on determining if there is a significant association between receiving a COVID-19 vaccine and the subsequent development of AD and MCI. Conducted in Seoul, South Korea, the study analyzed data from a random 50% sample of city residents aged 65 and above, totaling 558,017 individuals. Participants were divided into vaccinated and unvaccinated groups, with vaccinations including both mRNA and cDNA vaccines. Incidences of AD and MCI post-vaccination were identified using ICD-10 codes. Multivariable logistic and Cox regression analyses were employed to interpret the data, with patients having vascular dementia or Parkinson’s disease serving as control subjects. The study found an increased incidence of MCI and AD in vaccinated individuals, particularly those who received mRNA vaccines, within three months post-vaccination. Specifically, the mRNA vaccine group exhibited a significantly higher incidence of AD (odds ratio [OR]: 1.225; 95% confidence interval [CI]: 1.025–1.464; P = 0.026) and MCI (OR: 2.377; CI: 1.845–3.064; P < 0.001) compared to the unvaccinated group. However, no significant relationship was found with vascular dementia or Parkinson’s disease. Mechanisms of NeurodegenerationThe potential mechanisms underlying these observations involve several pathways. One hypothesis is related to the interaction of the SARS-CoV-2 spike protein with heparin and heparin-binding proteins in the brain, which are prone to self-assembly, aggregation, and fibrillation. Research suggests that the S1 region of the spike protein binds to these proteins, potentially acting as functional amyloid and forming toxic aggregates. These aggregates could seed the aggregation of misfolded brain proteins, leading to neurodegeneration. Additionally, the spike protein's ability to cross the blood-brain barrier raises concerns. Free spike protein particles have been detected in various organs, including the brain, where they might contribute to pathological processes. The spike protein's interaction with the ACE2 receptor and subsequent cellular entry could disturb protein synthesis machinery, endoplasmic reticulum and mitochondrial function, and increase the accumulation of misfolded proteins. This cascade of events could activate protein aggregation, mitochondrial oxidative stress, apoptosis, and ultimately neurodegeneration. There is also evidence from studies on other viruses, such as HSV-1, that viral proteins can bind to heparin and increase the aggregation of amyloid β (Aβ42) peptides, a hallmark of Alzheimer’s disease. Given that the receptor-binding domain of SARS-CoV-2's spike protein has several heparin-binding sites, a similar mechanism of neurodegeneration involving the aggregation of proteins like Aβ, α-synuclein, tau, prions, and TDP-43 could be at play in COVID-19. Preliminary evidence suggests a potential association between COVID-19 vaccination, especially with mRNA vaccines, and an increased incidence of Alzheimer’s disease and mild cognitive impairment. These findings highlight the need for further research to understand the mechanisms underlying this potential link, particularly focusing on vaccine-induced immune responses and their impact on neurodegenerative processes. Continuous monitoring and investigation into the long-term neurological impacts of COVID-19 vaccines are crucial to ensure comprehensive understanding and safety. referencesJee Hoon Roh, et al. “A Potential Association between COVID-19 Vaccination and Development of Alzheimer’s Disease.” QJM, 28 May 2024, https://doi.org/10.1093/qjmed/hcae103.
Grobbelaar, Lize M, et al. “SARS-CoV-2 Spike Protein S1 Induces Fibrin(Ogen) Resistant to Fibrinolysis: Implications for Microclot Formation in COVID-19.” MedRxiv (Cold Spring Harbor Laboratory), 8 Mar. 2021, https://doi.org/10.1101/2021.03.05.21252960. Idrees, Danish, and Vijay Kumar. “SARS-CoV-2 Spike Protein Interactions with Amyloidogenic Proteins: Potential Clues to Neurodegeneration.” Biochemical and Biophysical Research Communications, vol. 554, May 2021, pp. 94–98, https://doi.org/10.1016/j.bbrc.2021.03.100. Since the declaration of the COVID-19 pandemic by the World Health Organization (WHO) on March 11, 2020, over 13.5 billion doses of COVID-19 vaccines have been administered worldwide. This remarkable achievement in vaccine distribution highlights the urgent need for comprehensive vaccine safety monitoring, as very rare adverse events associated with COVID-19 vaccines may only become apparent after widespread administration. To address this need, the Safety Platform for Emergency Vaccines (SPEAC) initiative formulated a list of potential COVID-19 vaccine adverse events of special interest (AESI) in 2020. These AESI were selected based on various factors, including their associations with immunization, vaccine platforms, or adjuvants, as well as theoretical concerns related to immunopathogenesis. One flexible approach for assessing AESI is the comparison of observed AESI rates following vaccine introduction with expected rates based on historical periods pre-vaccine rollout. This method, known as observed vs. expected (OE) analysis, can rapidly detect potential vaccine safety signals. For example, OE analysis played a crucial role in identifying thrombosis with thrombocytopenia syndrome (TTS) as a safety signal, prompting the suspension of the AstraZeneca COVID-19 vaccine in certain countries. To further enhance vaccine safety monitoring, a global cohort study was conducted as part of the Global COVID Vaccine Safety (GCoVS) Project. This project, funded by the Centers for Disease Control and Prevention (CDC), involves multiple nations and aims to monitor COVID-19 vaccine safety on a global scale. Thirteen AESI were selected for evaluation, including neurological, hematologic, and cardiovascular conditions, which are as follows:
The study analyzed data from 10 sites across eight countries, comprising a total vaccinated population of 99,068,901 individuals. Notable findings include a statistically significant increase in Guillain-Barré syndrome (GBS) cases following the administration of the ChAdOx1 (India) vaccine and an increased risk of acute disseminated encephalomyelitis (ADEM) after the mRNA-1273 vaccine (Moderna). Hematologic conditions such as cerebral venous sinus thrombosis (CVST) and immune thrombocytopenia (ITP) also showed elevated risk ratios following certain vaccine doses. Similarly, cardiovascular conditions like myocarditis and pericarditis demonstrated increased risk ratios, particularly after mRNA vaccine doses (Pfizer, Moderna, AstraZeneca). Here is the raw data collected from the study: Here is a chart summarizing the raw data collected in the study: Overall, these findings underscore the importance of ongoing vaccine safety monitoring and highlight the value of global collaboration in assessing vaccine-related adverse events. By leveraging methodologies such as OE analysis and conducting comprehensive cohort studies, public health agencies can swiftly detect and respond to potential vaccine safety signals, ensuring the continued safety and effectiveness of COVID-19 vaccination efforts worldwide. referencesK. Faksova, et al. “COVID-19 Vaccines and Adverse Events of Special Interest: A Multinational Global Vaccine Data Network (GVDN) Cohort Study of 99 Million Vaccinated Individuals.” Vaccine, 1 Feb. 2024, https://doi.org/10.1016/j.vaccine.2024.01.100.
The documentary "War on Ivermectin" explores the contentious landscape surrounding the drug Ivermectin during the COVID-19 pandemic. It delves into the controversy surrounding the use of Ivermectin as a potential treatment for COVID-19 and the challenges it has faced from regulatory bodies and mainstream medical establishments.
The documentary presents perspectives from advocates of Ivermectin, who argue for its efficacy and safety in treating COVID-19. It may shed light on the resistance faced by proponents of Ivermectin, exploring factors such as media portrayal, regulatory decisions, and the broader implications for the treatment landscape. Additionally, the documentary might feature interviews with medical professionals, researchers, and individuals who have been affected by the debate over Ivermectin. It aims to provide a comprehensive overview of the complex and polarized discussions surrounding the drug in the context of the global response to the pandemic.
Safe and Effective: A Second Opinion shines a light on Covid-19 vaccine injuries and bereavements, but also takes an encompassing look at the systemic failings that appear to have enabled them. We look at leading analysis of pharmaceutical trials, the role of the MHRA in regulating these products, the role of the SAGE behavioural scientists in influencing policy and the role of the media and Big Tech companies in supressing free and open debate on the subject.
In this episode of The Highwire, Del Bigtree steps out on a high wire…literally! Additionally, he covers topics including the latest prevalence of autism, and the rise in sudden adult death syndrome (SADS). Featured guests on this show include Valerie Durham, Dr. Robert Malone, Dr. Richard Urso, and Dr. Pierre Kory.
In this episode of The Highwire, Del Bigtree highlights the Medical Freedom Movement Makes History; Freedom Convoy Exploding in Canada; Catastrophic New Covid Vaccine Data; Del’s Message to a Manic Mainstream Media; and Experts Second Opinion on The Pandemic.
Guest: Dr. Richard Urso
In this episode of The Highwire, Del Bigtree highlights The War on Pro Athletes; Ethics Expert Fired Over Mandate; Vaccine’s Flopping Against Omicron; New Docs Expose Fauci; ICAN Landmark Wins & Critique of SCOTUS Hearing.
Guests: Jonathan Isaac, Aaron Kheriaty M.D., Aaron Siri, Esq.
In this episode of The Highwire, Del Bigtree highlights A Look Back on HighWire’s Coverage of Covid; Welcome to the Party, Joe Rogan; ICAN Sues for V-Safe Data; Are You Suffering From Mass Delusional Psychosis?; and COVID Deaths Down, excess Deaths up? Are Government Payouts Manipulating US Covid Data?
Guests: Dr. Mark McDonald, AJ DePriest
Of those 34 eligible studies, 24 qualified for inclusion in the meta-analysis. They were separated into three groups: lockdown stringency index studies, shelter-in-placeorder (SIPO) studies, and specific NPI studies. An analysis of each of these three groups support the conclusion that lockdowns have had little to no effect on COVID-19 mortality. More specifically, stringency index studies find that lockdowns in Europe and the United States only reduced COVID-19 mortality by 0.2% on average. SIPOs were also ineffective, only reducing COVID-19 mortality by 2.9% on average. Specific NPI studies also find no broad-based evidence of noticeable effects on COVID-19 mortality. While this meta-analysis concludes that lockdowns have had little to no public health effects, they have imposed enormous economic and social costs where they have been adopted. In consequence, lockdown policies are ill-founded and should be rejected as a pandemic policy instrument.
In this episode of The Highwire, Del Bigtree highlights Firemen Fight for Freedom; British Mathematician Uncovers Disturbing UK Death Data; What is Wrong with Omicron?; Hospital Won’t Admit Tragic Vaccine Death?; and Big Pharma’s Faithful Jumping Ship
GUESTS: Fireman John Knox, Prof. Norman Fenton, Gina Doane, Deb Conrad, PA-C
In this episode of The Highwire, Del Bigtree highlights, FDA to Disclose Pfizer Data...in 56 years?!; Biden’s Mandate On Hold; CDC Whiffs On Natural Immunity; and Vaccine Expert’s Dire Mass Covid Vaccination Warning
Guests: Aaron Siri, Esq., Geert Vanden Bossche, PhD, DVM
In this episode of The Highwire, Del Bigtree highlights Big Bird Gets Covid Shot; Aaron Rodgers Throws Covid Touchdown; Homeschooling 101; Disruption of our DNA & Other Sins of ScienceGuests: Dana & Chelsea Broussard, Sam Sorbo
In this episode of The Highwire, Del Bigtree highlights D.C. Panel Highlights Vaccine Injuries; CDC Approves Covid Shot for Kids; Conflicting Data on Myocarditis in Kids; and America Stages Walkout
GUESTS: Brianne Dressen, Peter McCullough MD, Leigh Dundas, Esq.
In this episode of The HighWire featuring Del Bigtree, the discussion covers a range of critical topics, providing insights into the current state of affairs. The episode begins by addressing the concerns of growing tyranny in Australia, highlighting the challenging situations faced by the residents. Delving into the NBA standoff, the episode sheds light on the contentious issue surrounding vaccination requirements and the stance taken by players.
A significant segment of the episode focuses on the widespread job terminations due to vaccine mandates, with thousands facing the consequences of these policies. The 'Rome Declaration' gains attention as 7,200 individuals sign this new declaration, indicating a growing movement for vaccine choice and personal freedom. The precarious situation faced by a New York restaurant under threat due to vaccine-related regulations is explored, exemplifying the challenges businesses encounter in navigating these uncertain times. The episode also features a meeting between two prominent figures in the COVID landscape, offering valuable perspectives on the ongoing situation. Guests Taylor and Frank Winterstein, Irene Siderakis, and Deborah Conrad, PA-C contribute to the discussion, providing expert insights and sharing their experiences. The overarching themes of Covid Giants, Vaccine Choice, the Rome Declaration, BidensBooster, and the VAERS Whistleblower underscore the episode's commitment to addressing pressing issues and fostering informed discussions around these critical topics.
In this episode of The Highwire, Del breaks an exclusive newly-unredacted bombshell Fauci email; Dr. Jeffery Barke tells us why not to buy into Delta fears; CDC lying about natural immunity; Former Federal Official Catherine Austin Fitts’ urgent warning for all Americans.
Dr. Peter McCullough, joins the Highwire again, this time to discuss the serious problem with the efficacy of the COVID-19 vaccines and how mass vaccination is creating this runaway train of a pandemic. In this episode, Del and Dr. McCullough talk about vaccine efficacy, the delta variant, natural immunity, and asymmetric reporting, among other topics.
Geert Vanden Bossche, PhD, DVM, is an internationally recognized vaccine research expert and developer. He has a long list of companies and organizations he’s worked with on vaccine discovery and preclinical research, including the head of the Vaccine Development Office at the German Centre for Infection Research, GSK, Novartis, Solvay Biologicals, and Bill & Melinda Gates Foundation. Dr Vanden Bossche also coordinated the Ebola vaccine program at GAVI (Global Alliance for Vaccines and Immunization) and contributed to the implementation of an integrated vaccine work plan in collaboration with Global Health Partners (WHO, Bill & Melinda Gates Foundation, CDC, UNICEF), regulators (FDA) and vaccine manufacturers to enable timely deployment or stockpiling of Ebola vaccine candidates.
He is board-certified in Virology and Microbiology, the author of over 30 publications, and inventor of a patent application for universal vaccines. He currently works as an independent vaccine research consultant. In this following video, he shares his perspective on mass vaccination of SARS-CoV2, and highlights the principle of using a prophylactic vaccine in the midst of a pandemic, which is likely to create more viral variants in the process. Bossche states that the multiple emerging, “much more infectious” viral variants, are already examples of “immune escape” from our ‘innate immunity’, and were most-likely created by the government interventions themselves; the so-called Non-Pharmacological Interventions (NPIs) – i.e. lockdowns and cloth facial coverings. Unofficially, but also more aptly known as the Non-Scientific Interventions. He believes that:
He states that to “fully escape”, the highly mutable virus, “only needs to add another few mutations in its receptor-binding domain”. Below is his open letter to the WHO, issued March 6th, 2021. Open Letter to the World Health Organization
Geert Vanden Bossche, DMV, PhD, independent virologist and vaccine expert, formerly employed at GAVI and The Bill & Melinda Gates Foundation.
To all authorities, scientists and experts around the world, to whom this concerns: the entire world population. I am all but an antivaxxer. As a scientist I do not usually appeal to any platform of this kind to make a stand on vaccine-related topics. As a dedicated virologist and vaccine expert I only make an exception when health authorities allow vaccines to be administered in ways that threaten public health, most certainly when scientific evidence is being ignored. The present extremely critical situation forces me to spread this emergency call. As the unprecedented extent of human intervention in the Covid-19- pandemic is now at risk of resulting in a global catastrophe without equal, this call cannot sound loudly and strongly enough. As stated, I am not against vaccination. On the contrary, I can assure you that each of the current vaccines have been designed, developed and manufactured by brilliant and competent scientists. However, this type of prophylactic vaccines are completely inappropriate, and even highly dangerous, when used in mass vaccination campaigns during a viral pandemic. Vaccinologists, scientists and clinicians are blinded by the positive short-term effects in individual patents, but don’t seem to bother about the disastrous consequences for global health. Unless I am scientifically proven wrong, it is difficult to understand how current human interventions will prevent circulating variants from turning into a wild monster. Racing against the clock, I am completing my scientific manuscript, the publication of which is, unfortunately, likely to come too late given the ever increasing threat from rapidly spreading, highly infectious variants. This is why I decided to already post a summary of my findings as well as my keynote speech at the recent Vaccine Summit in Ohio on LinkedIn. Last Monday, I provided international health organizations, including the WHO, with my analysis of the current pandemic as based on scientifically informed insights in the immune biology of Covid-19. Given the level of emergency, I urged them to consider my concerns and to initiate a debate on the detrimental consequences of further ‘viral immune escape’. For those who are no experts in this field, I am attaching below a more accessible and comprehensible version of the science behind this insidious phenomenon. While there is no time to spare, I have not received any feedback thus far. Experts and politicians have remained silent while obviously still eager to talk about relaxing infection prevention rules and 'springtime freedom'. My statements are based on nothing else but science. They shall only be contradicted by science. While one can barely make any incorrect scientific statements without being criticized by peers, it seems like the elite of scientists who are currently advising our world leaders prefer to stay silent. Sufficient scientific evidence has been brought to the table. Unfortunately, it remains untouched by those who have the power to act. How long can one ignore the problem when there is at present massive evidence that viral immune escape is now threatening humanity? We can hardly say we didn't know - or were not warned. In this agonizing letter I put all of my reputation and credibility at stake. I expect from you, guardians of mankind, at least the same. It is of utmost urgency. Do open the debate. By all means: turn the tide! PUBLIC HEALTH EMERGENCY OF INTERNATIONAL CONCERN Why mass vaccination amidst a pandemic creates an irrepressible monster THE key question is: why does nobody seem to bother about viral immune escape? Let me try to explain this by means of a more easily understood phenomenon: Antimicrobial resistance. One can easily extrapolate this scourge to resistance to our self-made ‘antiviral antibiotics’. Indeed, antibodies (Abs) produced by our own immune system can be considered self-made antiviral antibiotics, regardless of whether they are part of our innate immune system (so-called ‘natural’ Abs’) or elicited in response to specific pathogens (resulting in so-called ‘acquired’ Abs). Natural Abs are not germ-specific whereas acquired Abs are specifically directed at the invading pathogen. At birth, our innate immune system is ‘unexperienced’ but well-established. It protects us from a multitude of pathogens, thereby preventing these pathogens from causing disease. As the innate immune system cannot remember the pathogens it encountered (innate immunity has no so-called ‘immunological memory’), we can only continue to rely on it provided we keep it ‘trained’ well enough. Training is achieved by regular exposure to a myriad of environmental agents, including pathogens. However, as we age, we will increasingly face situations where our innate immunity (often called ‘the first line of immune defense’) is not strong enough to halt the pathogen at the portal of entry (mostly mucosal barriers like respiratory or intestinal epithelia). When this happens, the immune system has to rely on more specialized effectors of our immune system (i.e., antigen-specific Abs and T cells) to fight the pathogen. So, as we grow up, we increasingly mount pathogen-specific immunity, including highly specific Abs. As those have stronger affinity for the pathogen (e.g., virus) and can reach high concentrations, they can quite easily outcompete our natural Abs for binding to the pathogen/virus. It is precisely this type of highly specific, high affinity Abs that current Covid-19 vaccines are inducing. Of course, the noble purpose of these Abs is to protect us against Covid-19. So, why then should there be a major concern using these vaccines to fight Covid-19? Well, similar to the rules applying to classical antimicrobial antibiotics, it is paramount that our self-made ‘antiviral antibiotics’ are made available in sufficient concentration and are tailored at the specific features of our enemy. This is why in case of bacterial disease it is critical to not only chose the right type of antibiotic (based on the results from an antibiogram) but to also take the antibiotic for long enough (according to the prescription). Failure to comply with these requirements is at risk of granting microbes a chance to survive and hence, may cause the disease to fare up. A very similar mechanism may also apply to viruses, especially to viruses that can easily and rapidly mutate (which is, for example, the case with Coronaviruses); when the pressure exerted by the army’s (read: population’s) immune defense starts to threaten viral replication and transmission, the virus will take on another coat so that it can no longer be easily recognized and, therefore, attacked by the host immune system. The virus is now able to escape immunity (so-called: ‘immune escape’). However, the virus can only rely on this strategy provided it still has room enough to replicate. Viruses, in contrast to the majority of bacteria, must rely on living host cells to replicate. This is why the occurrence of ‘escape mutants’ isn’t too worrisome as long as the likelihood for these variants to rapidly find another host is quite remote. However, that’s not particularly the case during a viral pandemic! During a pandemic, the virus is spreading all over the globe with many subjects shedding and transmitting the virus (even including asymptomatic ‘carriers’). The higher the viral load, the higher the likelihood for the virus to bump into subjects who haven’t been infected yet or who were infected but didn’t develop symptoms. Unless they are sufficiently protected by their innate immune defense (through natural Abs), they will catch Covid-19 disease as they cannot rely on other, i.e., acquired Abs. It has been extensively reported, indeed, that the increase in S (spike)-specific Abs in asymptomatically infected people is rather limited and only short-lived. Furthermore, these Abs have not achieved full maturity. The combination of viral infection on a background of suboptimal Ab maturity and concentration enables the virus to select mutations allowing it to escape the immune pressure. The selection of those mutations preferably occurs in the S protein as this is the viral protein that is responsible for viral infectiousness. As the selected mutations endow the virus with increased infectious capacity, it now becomes much easier for the virus to cause severe disease in infected subjects. The more people develop symptomatic disease, the better the virus can secure its propagation and perpetuation (people who get severe disease will shed more virus and for a longer period of time than asymptomatically infected subjects do). Unfortunately enough, the short-lived rise in S-specific Abs does, however, suffice to bypass people’s innate/natural Ab. Those are put out of business as their affinity for S is lower than the affinity of S-specific Abs. This is to say that with an increasing rate of infection in the population, the number of subjects who get infected while experiencing a momentary increase in Specific Abs will steadily increase. Consequently, the number of subjects who get infected while experiencing a momentary decrease in their innate immunity will increase. As a result, a steadily increasing number of subjects will become more susceptible to getting severe disease instead of showing only mild symptoms (i.e., limited to the upper respiratory tract) or no symptoms at all. During a pandemic, especially youngsters will be affected by this evolution as their natural Abs are not yet largely suppressed by a panoply of ‘acquired’, antigen-specific Abs. Natural Abs, and natural immunity in general, play a critical role in protecting us from pathogens as they constitute our first line of immune defense. In contrast to acquired immunity, innate immune responses protect against a large spectrum of pathogens (so don’t compromise or sacrifice your innate immune defense!). Because natural Abs and innate immune cells recognize a diversified spectrum of foreign (i.e., non-self) agents (only some of which have pathogenic potential), it’s important, indeed, to keep it sufficiently exposed to environmental challenges. By keeping the innate immune system (which, unfortunately, has no memory!) TRAINED, we can much more easily resist germs which have real pathogenic potential. It has, for example, been reported and scientifically proven that exposure to other, quite harmless Coronaviruses causing a ‘common cold ’ can provide protection, although short-lived, against Covid-19 and its loyal henchmen (i.e., the more infectious variants). Suppression of innate immunity, especially in the younger age groups, can, therefore, become very problematic. There can be no doubt that lack of exposure due to stringent containment measures implemented as of the beginning of the pandemic has not been beneficial to keeping people’s innate immune system well trained. As if this was not already heavily compromising innate immune defense in this population segment, there comes yet another force into play that will dramatically enhance morbidity and mortality rates in the younger age groups: MASS VACCINATION of the ELDERLY. The more extensively the later age group will be vaccinated and hence, protected, the more the virus is forced to continue causing disease in younger age groups. This is only going to be possible provided it escapes to the S-specific Abs that are momentarily raised in previously asymptomatically infected subjects. If the virus manages to do so, it can benefit from the (momentarily) suppressed innate immunity, thereby causing disease in an increasing number of these subjects and ensuring its own propagation. Selecting targeted mutations in the S protein is, therefore, the way to go in order for the virus to enhance its infectiousness in candidates that are prone to getting the disease because of a transient weakness of their innate immune defense. But in the meantime, we’re also facing a huge problem in vaccinated people as they’re now more and more confronted with infectious variants displaying a type of S protein that is increasingly different from Author: Geert Vanden Bossche, DVM, PhD (March 6, 2021) – https://www.linkedin.com/in/geertvandenbossche/ the S edition comprised with the vaccine (the later edition originates from the original, much less infectious strain at the beginning of the pandemic). The more variants become infectious (i.e., as a result of blocking access of the virus to the vaccinated segment of the population), the less vaccinal Abs will protect. Already now, lack of protection is leading to viral shedding and transmission in vaccine recipients who are exposed to these more infectious strains (which, by the way, increasingly dominate the field). This is how we are currently turning vaccines into asymptomatic carriers shedding infectious variants. At some point, in a likely very near future, it’s going to become more profitable (in term of ‘return on selection investment’) for the virus to just add another few mutations (maybe just one or two) to the S protein of viral variants (already endowed with multiple mutations enhancing infectiousness) in an attempt to further strengthen its binding to the receptor (ACE-2) expressed on the surface of permissive epithelial cells. This will now allow the new variant to outcompete vaccinal Abs for binding to the ACE receptor. This is to say that at this stage, it would only take very few additional targeted mutations within the viral receptor-binding domain to fully resist specific anti-Covid-19 Abs, regardless whether the later are elicited by the vaccine or by natural infection. At that stage, the virus will, indeed, have managed to gain access to a huge reservoir of subjects who have now become highly susceptible to disease as their S-specific Abs have now become useless in terms of protection but still manage to provide for long-lived suppression of their innate immunity (i.e., natural infection, and especially vaccination, elicit relatively long-lived specific Ab titers). The susceptible reservoir comprises both, vaccinated people and those who’re left with sufficient S-specific Abs due to previous Covid-19 disease). So, MISSION ACCOMPLISHED for Covid-19 but a DISASTROUS SITUATION for all vaccinated subjects and Covid-19 seropositive people as they’ve now lost both, their acquired and innate immune defense against Covid-19 (while highly infectious strains are circulating!). That’s ‘one small step for the virus, one giant catastrophe for mankind’, which is to say that we’ll have whipped up the virus in the younger population up to a level that it now takes little effort for Covid-19 to transform into a highly infectious virus that completely ignores both the innate arm of our immune system as well as the adaptive/acquired one (regardless of whether the acquired Abs resulted from vaccination or natural infection). The effort for the virus is now becoming even more negligible given that many vaccine recipients are now exposed to highly infectious viral variants while having received only a single shot of the vaccine. Hence, they are endowed with Abs that have not yet acquired optimal functionality. There is no need to explain that this is just going to further enhance immune escape. Basically, we’ll very soon be confronted with a super-infectious virus that completely resists our most precious defense mechanism: The human immune system. From all of the above, it’s becoming increasingly difficult to imagine how the consequences of the extensive and erroneous human intervention in this pandemic are not going to wipe out large parts of our human population. One could only think of very few other strategies to achieve the same level of efficiency in turning a relatively harmless virus into a bioweapon of mass destruction. It’s certainly also worth mentioning that mutations in the S protein (i.e., exactly the same protein that is subject to selection of escape mutations) are known to enable Coronaviruses to cross species barriers. This is to say that the risk that vaccine-mediated immune escape could allow the virus to jump to other animal species, especially industrial livestock (e.g., pig and poultry farms), is not negligible. These species are already known to host several different Coronaviruses and are usually housed in farms with high stocking density. Similar to the situation with influenza virus, these species could than serve as an additional reservoir for SARS-COVID-2 virus. As pathogens have co-evolved with the host immune system, natural pandemics of acute self-limiting viral infections have been shaped such as to take a toll on human lives that is not higher than strictly required. Due to human intervention, the course of this pandemic has been thoroughly disturbed as of the very beginning. Widespread and stringent infection prevention measures combined with mass vaccination campaigns using inadequate vaccines will undoubtedly lead to a situation where the pandemic is getting increasingly ‘out of control’. Paradoxically, the only intervention that could offer a perspective to end this pandemic (other than to let it run its disastrous course) is …VACCINATION. Of course, the type of vaccines to be used would be completely different of conventional vaccines in that they’re not inducing the usual suspects, i.e., B and T cells, but NK cells. There is, indeed, compelling scientific evidence that these cells play a key role in facilitating complete elimination of Covid-19 at an early stage of infection in symptomatically infected subjects. NK cells are part of the cellular arm of our innate immune system and, alike natural Abs, they are capable of recognizing and attacking a broad and diversified spectrum of pathogenic agents. There is a sound scientific rationale to assume that it is possible to ‘prime’ NK cells in ways for them to recognize and kill Coronaviruses at large (include all their variants) at an early stage of infection. NK cells have increasingly been described to be endowed with the capacity to acquire immunological memory. By educating these cells in ways that enable them to durably recognize and target Coronavirus-infected cells, our immune system could be perfectly armed for a targeted attack to the universe of Coronaviruses prior to exposure. As NK cell-based immune defense provides sterilizing immunity and allows for broadspectrum and fast protection, it is reasonable to assume that harnessing our innate immune cells is going to be the only type of human intervention left to halt the dangerous spread of highly infectious Covid-19 variants. If we, human beings, are committed to perpetuating our species, we have no choice left but to eradicate these highly infectious viral variants. This will, indeed, require large vaccination campaigns. However, NK cell-based vaccines will primarily enable our natural immunity to be better prepared (memory!) and to induce herd immunity (which is exactly the opposite of what current Covid-19 vaccines do as those increasingly turn vaccine recipients into asymptomatic carriers who are shedding virus). So, there is not one second left for gears to be switched and to replace the current killer vaccines by life-saving vaccines. I am appealing to the WHO and all stakeholders involved, no mater their conviction, to immediately declare such acton as THE SINGLE MOST IMPORTANT PUBLIC HEALTH EMERGENCY OF INTERNATIONAL CONCERN.
CDC Spin on New Mask Data; Celebrity Catches Fauci Lying!; Expert Warns of Coming Covid Vaccine Disaster; Hell in the Holy Land
Dr. David Martin, founder and chairman of M-CAM Inc, challenges our presuppositions about the new mRNA Covid-19 vaccines. Quoting the pharmaceutical companies themselves, David suggests that these are not vaccines, but, in actuality, gene therapy. He explains what the vaccines may do to us, what they are promising they can do for us, and how to distinguish the difference.
Transcript
AFLDS founder Simone Gold, MD, JD, FABEM, “the doctor who went viral,” is a board-certified emergency physician and author of the best-selling book “I Do Not Consent: My Fight Against Medical Cancel Culture.” She graduated from Chicago Medical School before attending Stanford University Law School to earn her Juris Doctorate degree. Dr. Gold worked in Washington, D.C. for the Surgeon General, as well as for the Chairman of the U.S. Senate Labor and Human Resources Committee.
Dr. Gold is a frequent guest on media outlets across the country. She has appeared in USA Today, the Associated Press, the Guardian (UK), New York Times, and many other publications. She has been featured on such nationally syndicated programs as The Tucker Carlson Show, The Ingraham Angle, The Glenn Beck Show, The Charlie Kirk Show, The Dennis Prager Show, Day Star Television, and others. In July 2020, she organized the first-ever America’s Frontline Doctors White Coat Summit in Washington, D.C., which drew 20 million views online. Dr. Gold is America’s leading voice of common sense and scientific clarity in the fight against COVID-19. Zach Bush MD is a physician specializing in internal medicine, endocrinology and hospice care. He is an internationally recognized educator and thought leader on the microbiome as it relates to health, disease, and food systems. Dr Zach founded Seraphic Group and the nonprofit Farmer’s Footprint to develop root-cause solutions for human and ecological health. His passion for education reaches across many disciplines, including topics such as the role of soil and water ecosystems in human genomics, immunity, and gut/brain health. His education has highlighted the need for a radical departure from chemical farming and pharmacy, and his ongoing efforts are providing a path for consumers, farmers, and mega-industries to work together for a healthy future for people and planet.
Show Notes
In this conversation, Dr. Tom Cowan and Sally Fallon Morrell discuss The Contagion Myth.
The official explanation for today’s COVID-19 pandemic is a “dangerous, infectious virus.” This is the rationale for isolating a large portion of the world’s population in their homes so as to curb its spread. From face masks to social distancing, from antivirals to vaccines, these measures are predicated on the assumption that tiny viruses can cause serious illness and that such illness is transmissible person-to-person. It was Louis Pasteur who convinced a skeptical medical community that contagious germs cause disease; his “germ theory” now serves as the official explanation for most illness. However, in his private diaries, he states unequivocally that in his entire career he was not once able to transfer disease with a pure culture of bacteria (he obviously wasn’t able to purify viruses at that time). He admitted that the whole effort to prove contagion was a failure, leading to his famous death bed confession that “the germ is nothing, the terrain is everything.” While the incidence and death statistics for COVID-19 may not be reliable, there is no question that many people have taken sick with a strange new disease—with odd symptoms like gasping for air and “fizzing” feelings—and hundreds of thousands have died. Many suspect that the cause is not viral but a kind of pollution unique to the modern age—electromagnetic pollution. Today we are surrounded by a jangle of overlapping and jarring frequencies—from power lines to the fridge to the cell phone. It started with the telegraph and progressed to worldwide electricity, then radar, then satellites that disrupt the ionosphere, then ubiquitous Wi-Fi. The most recent addition to this disturbing racket is fifth-generation wireless—5G. In The Contagion Myth: Why Viruses (including Coronavirus) are Not the Cause of Disease, bestselling authors Thomas S. Cowan, MD, and Sally Fallon Morell tackle the true causes of COVID-19. On September 26, 2019, 5G wireless was turned on in Wuhan, China (and officially launched November 1) with a grid of about ten thousand antennas—more antennas than exist in the whole United States, all concentrated in one city. A spike in cases occurred on February 13, the same week that Wuhan turned on its 5G network for monitoring traffic. Illness has subsequently followed 5G installation in all the major cities in America. Since the dawn of the human race, medicine men and physicians have wondered about the cause of disease, especially what we call “contagions,” numerous people ill with similar symptoms, all at the same time. Does humankind suffer these outbreaks at the hands of an angry god or evil spirit? A disturbance in the atmosphere, a miasma? Do we catch the illness from others or from some outside influence? As the restriction of our freedoms continues, more and more people are wondering whether this is true. Could a packet of RNA fragments, which cannot even be defined as a living organism, cause such havoc? Perhaps something else is involved—something that has upset the balance of nature and made us more susceptible to disease? Perhaps there is no “coronavirus” at all; perhaps, as Pasteur said, “the germ is nothing, the terrain is everything.” From RT:
Now, we have a thing called a messenger RNA vaccine (mRNA). RNA is, effectively, a single strand of DNA – the double helix that sits within our cells and makes up our genetic code. Many viruses are made up of a single strand of RNA, surrounded by a protein sphere. They enter the cell, take over the replication systems, make thousands of copies of themselves, then exit the cell. Sometimes killing the cell as they do so, sometimes exiting more gently. Covid19 (Sars-Cov2) is an RNA virus. Knowing this, rather than attempting to create a weakened virus, which can take years, or break the virus into bits, the vaccine researchers decided to use Sars-Cov2’s RNA against itself. To do this, they isolated the section of RNA which codes for the ‘spike’ protein – which is the thing the virus uses as a ‘key’ to enter cells. They then worked out how to insert this small section of RNA, messenger RNA, into the cell, where it takes over a part of the protein replication mechanisms that sit inside all cells. They turn the mechanism into a 3D printer, churning out copies of the spike protein. These spike proteins then leave the cell – somehow or other, this bit is unclear. The immune system comes across them, recognises them as ‘alien’ and attacks. In doing so, antibodies are created, and the immune memory system kicks into action. If, later on, a Sars-Cov2 virus gets into the body, the immune system fires up and attacks the remembered spike protein. Hopefully killing the entire virus. This is all, certainly very clever stuff. What, as they say, could possibly go wrong? The first thing to say is that, with something this new, we don’t really know. It could be that it is absolutely 100 percent safe. We are told that none of the mRNA can get into the nucleus of the cell, where it could become incorporated into the DNA. I hope so. Could it trigger an immune cascade? I hope not. I know that the researchers will be looking very, very, closely at the novel safety issues that could emerge. If they are not, they damned well should be. However, the timelines here are very short. It normally takes many years to create safe and effective vaccines. Here is it happening in, effectively, weeks. Dr. Palevsky is a NYS licensed pediatrician, who utilizes a holistic approach to children’s wellness and illness. Dr. Palevsky received his medical degree from the NYU School of Medicine in 1987, completed a three-year pediatric residency at The Mount Sinai Hospital in NYC in 1990, and served as a pediatric fellow in the ambulatory care out-patient department at Bellevue Hospital, NYC, from 1990-1991. Since 1991, his clinical experience includes working in pediatric emergency and intensive care medicine, in-patient, and out-patient pediatric medicine, neonatal intensive care medicine, newborn and delivery room medicine, and conventional, holistic and integrative pediatric private practice. Dr. Palevsky is a diplomate of the American Board of Integrative Holistic Medicine, and Past–President of the American Holistic Medical Association. He received his pediatric board certification in 1990, and passed his pediatric board recertification exams in 1997, 2004, and 2011.
In his current pediatric practice, Dr. Palevsky offers well-child examinations, consultations and educational programs to families and practitioners in the areas of preventive and holistic health; childhood development; lifestyle changes; nutrition for adults, infants and children; safe, alternative treatments for common and difficult to treat acute and chronic pediatric and adult conditions; vaccination controversies; mindful parenting; and rethinking the medical paradigm. Additionally, he teaches holistic integrative pediatric & adolescent medicine to parents, and medical and allied health professionals, both nationally & internationally, and is available for speaking engagements worldwide. |
The Awareness domain contains research, news, information, observations, and ideas at the level of self in an effort to intellectualize health concepts.
The Lifestyle domain builds off intellectual concepts and offers practical applications.
Taking care of yourself is at the core of the other domains because the others depend on your health and wellness.
Archives
October 2024
Categories
All
|